Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Replimune Announces First Patients Dosed in a Phase 1/2 Clinical Trial of its RP1 Oncolytic Immunotherapy in Patients With Advanced Solid Tumors


WOBURN, Massachusetts, November 14, 2017 /PRNewswire/ --

Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today that the first cohort of patients has been dosed in a phase 1/2 clinical trial of RP1 in patients with advanced solid tumors. RP1 is the first product candidate generated from the Company's Immulytictm platform, designed to maximize systemic anti-tumor immune activation.

     (Logo: http://mma.prnewswire.com/media/603702/Replimune_Group_Logo.jpg )

"RP1 combines multiple compelling mechanisms of action into one therapeutic agent," said Howard Kaufman, M.D., chief medical officer of Replimune. "We are enthusiastic about the potential for RP1 to activate both innate and adaptive immunity to induce a potent and broad based anti-tumor immune response directly in situ in the patient, an approach which is expected to be highly synergistic with immune checkpoint blockade."

The Phase 1/2 clinical trial is designed in two parts to assess the safety, tolerability and preliminary efficacy of RP1 alone and in combination with anti-PD1 therapy. The first part of the study, being conducted in patients with advanced solid tumors, will assess the safety of RP1 and determine the optimal dose for use in the second part of the study. Part 2 of the study will further evaluate safety and also assess the preliminary efficacy of RP1 administered in combination with anti-PD1 therapy in cohorts of patients with specific solid tumor types.

"The initiation of this first clinical trial with RP1 marks a major milestone for Replimune," said Robert Coffin, Ph.D., co-founder & CEO of Replimune. "We believe that RP1 and follow on therapies from our Immulytictm platform have the potential to become a differentiated and foundational cornerstone of combination cancer immunotherapy."

Replimune's Immulytictm platform is designed to maximize systemic anti-tumor immune activation, in particular to tumor neo-antigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins directly to tumors. In addition to direct tumor destruction, RP1 is intended to induce an anti-tumor immune response that is unique to the individual patient's tumor, offering the benefits of a personalized therapy but using an off-the-shelf, practical approach.

About RP1 & Replimune's Pipeline

RP1 is Replimune's first Immulytictm product to enter the clinic, and is based on a proprietary new strain of herpes simplex virus engineered for tumor selectivity and enhanced systemic potency, including through the expression of a potent fusogenic glycoprotein. This is intended to greatly increase tumor killing potency, result in highly immunogenic cell death, and to be highly synergistic with immune checkpoint blockade. Follow on products (RP2 & RP3), one of which is intended to enter clinical development in 2018, further express an anti-CTLA-4 antibody-like molecule and/or optimized immune co-stimulatory pathway activating ligands.

Immulytictm products are intended to be administered by direct injection into solid tumors, including through imaging guidance for deeper tumors using approaches similar to those used to take biopsies. This maximizes virus mediated cell death, which is required for the optimal activation of systemic immunity. In addition, direct injection provides the most efficient delivery of virus encoded immune activating proteins into the tumor, limiting systemic exposure and reducing potential toxicities. The alternative of intravenous dosing increases dilution in the blood, decreasing efficacy and rendering anything other than very short-term dosing futile due to the rapid induction of antiviral immune responses.

About Oncolytic Immunotherapy

Oncolytic immunotherapy is an emerging class of cancer therapy which exploits the ability of viruses to selectively replicate in and kill tumors, while at the same time inducing a potent, patient-specific, anti-tumor immune response. Oncolytic viruses have the unique ability to generate an autologous vaccine to the patient's particular complement of tumor antigens, including neo-antigens, in situ in the patient with a truly off-the-shelf approach. While clear single agent clinical activity has been achieved with oncolytic immunotherapy, particular synergy may be observed in combination with immune checkpoint blockade and other immune-modulatory approaches.

About Replimune 

Replimune Group Inc, headquartered in Woburn, MA, was founded in March 2015 to develop the next generation of 'oncolytic immunotherapies' for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company's Immulytictm platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development and to combine with other immuno-oncology products with complementary mechanisms of action at an early stage.  For more information, please visit  http://www.replimune.com.

Investor Inquiries
Pamela Esposito, Ph.D.
Replimune Group Inc.
[email protected]

Media Inquiries 
Lissette Steele
Verge Scientific Communications
[email protected]

SOURCE Replimune Group Inc.


These press releases may also interest you

at 07:48
Gold's Gym SoCal ? the original home of fitness workouts ? celebrates its 35th anniversary, marking three and a half decades of unparalleled dedication to health, wellness, and community. To coincide with the milestone, Gold's Gym SoCal is unveiling...

at 07:44
Acclaro Medical announced that its UltraClear® 2910 nm fiber laser was awarded the "Best Laser Treatment for All Skin Tones - 2024" from NewBeauty Magazine. The win in this highly regarded and very popular publication is a repeat favorite for the...

at 06:45
The "Global Pediatric Interventional Cardiology Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to  ResearchAndMarkets.com's offering. The Global Pediatric...

at 06:30
The "Sample Preparation Market by Product (Workstation, Instrument {Pipette, Washer, Centrifuge, Grinder}, Consumable {Kits, Filters, Plates}) Technique (Solid Phase Extraction, Purification) Application (Drug Discovery, Diagnostic) - Global Forecast...

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 06:08
ConTemporary Locums, a physician-focused medical staffing company, is ushering in a new era with a bold rebrand: Era Locums. This brand evolution marks a commitment to continued innovation and a deeper connection with the company's physician and...



News published on and distributed by: